Taurochenodeoxycholic acid

製品コードS3865 バッチS386504

印刷

化学情報

Chemical Structure Synonyms Taurochenodeoxycholate, TCDCA, 12-Deoxycholyltaurine, Chenodeoxycholyltaurine, Chenyltaurine Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C26H45NO6S
分子量 499.70 CAS No. 516-35-8
Solubility (25°C)* 体外 DMSO 100 mg/mL (200.12 mM)
Water 100 mg/mL (200.12 mM)
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Taurochenodeoxycholic acid (Taurochenodeoxycholate, TCDCA, Chenodeoxycholyltaurine), a bile acid formed in the liver of most species, is used as a cholagogue and choleretic.
in vitro Taurochenodeoxycholic acid (TUDCA) induces dissociation of CD34+ HSCs from stromal cells by decreasing adhesion molecule expression. It induces bone marrow stem cell mobilization and differentiation into endothelial progenitor cells (EPCs) and enhances EPC proliferation, invasion, and tube formation via Akt and ERK activation[1]. TCDCA induces the apoptosis process through the activation of caspase cascade in macrophages, and this process may be involved in PKC/JNK signaling pathway[2].
in vivo TUDCA has neuroprotective effects in neuronal cultures and positive effects on ischemia reperfusion in animal models, reducing infarct area and inflammation via attenuation of endoplasmic reticulum (ER) stress. TUDCA is incorporated into target cells via organic anion transporter (OATP) 2, OATP8, and the Na+‐taurocholate cotransporting polypeptide (NTCP). TUDCA inhibits neointimal hyperplasia by promoting apoptosis of smooth muscle cells via induction of MAP kinase phosphatase‐1 (MKP‐1) expression. In addition, TUDCA protects the hepatocytes and restores glucose homeostasis by reducing ER stress. TUDCA enhances neovascularization in vivo[1]. TCDCA in dosages of 0.05 and 0.1g/kg can extremely significantly decrease the pulmonary coefficient in the model mice. TCDCA in a dosage of 0.2g/kg significantly decreases the pulmonary coefficient in the model mice (P<0.05); TCDCA in dosages of 0.05 and 0.1g/kg significantly reduce the pathological damages on their lungs; TCDCA can extremely significantly decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice (P>0.01), the expression level of MMP-9 extremely significantly increased (P>0.01), while it has no significant effects on MMP2. Thus, TCDCA has antagonistic actions on pulmonary fibrosis in mice[3].

プロトコル(参考用のみ)

細胞アッセイ 細胞株 CD34+ HSCs
濃度 50 and 100 μM
反応時間 5 h
実験の流れ --
動物実験 動物モデル C57BL/6 mice
投薬量 20 mg/kg
投与方法 oral adminitration

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinoma [ Nat Commun, 2021, 12(1):6479] PubMed: 34759281
Antibiotic-modulated microbiome suppresses lethal inflammation and prolongs lifespan in Treg-deficient mice. [ Microbiome, 2019, 7(1):145] PubMed: 31699146

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。